HARMONY BIOSCIENCES HOLDINGS (HRMY)
US4131971040 - Common Stock
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...
Harmony Biosciences Holdings Breaks Above 200-Day Moving Average - Bullish for HRMY
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2023.
Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line (NASDAQ:HRMY)
Harmony Biosciences reports Q4 non-GAAP EPS of $0.73, missing estimates by $0.18.
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%,...
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) granted priority review for its...
Harmony gets FDA orphan drug status for Prader-Willi treatment (NASDAQ:HRMY)
Harmony Biosciences (HRMY) has received orphan drug designation from the FDA for its drug pitolisant in the treatment of Prader-Willi syndrome. Read more here.
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on...
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks.
Commit To Buy Harmony Biosciences Holdings At $30, Earn 28.2% Annualized Using Options
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue...
HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
Why Harmony Biosciences Stock Got Slammed Today
The commercial-stage company was dinged by a bearish new take from a researcher.
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
Although Russell 2000 stocks may operate in the lightweight category, these entities could potentially provide a knockout punch.
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal...
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
HARMONY BIOSCIENCES RANKED AMONG TOP 25 FASTEST-GROWING COMPANIES IN NORTH AMERICA ON THE 2023 DELOITTE TECHNOLOGY FAST 500™
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...